BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17635895)

  • 1. Improving detection of adverse effects of marketed drugs.
    Klein DF; O'Brien CP
    JAMA; 2007 Jul; 298(3):333-4. PubMed ID: 17635895
    [No Abstract]   [Full Text] [Related]  

  • 2. AERS spider: an online interactive tool to mine statistical associations in Adverse Event Reporting System.
    Grigoriev I; zu Castell W; Tsvetkov P; Antonov AV
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):795-801. PubMed ID: 24677538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
    Kuehn BM
    JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
    [No Abstract]   [Full Text] [Related]  

  • 4. Signal detection using change point analysis in postmarket surveillance.
    Xu Z; Kass-Hout T; Anderson-Smits C; Gray G
    Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):663-8. PubMed ID: 25903221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse drug reactions.
    Roswell R; Van Diepen LR; Jones JK; Hicks WE
    Lancet; 2001 Feb; 357(9255):561-2. PubMed ID: 11229704
    [No Abstract]   [Full Text] [Related]  

  • 6. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Extreme duplication' in the US FDA Adverse Events Reporting System database.
    Hauben M; Reich L; DeMicco J; Kim K
    Drug Saf; 2007; 30(6):551-4. PubMed ID: 17536881
    [No Abstract]   [Full Text] [Related]  

  • 8. The benefits of data mining.
    Bone A; Houck K
    Elife; 2017 Aug; 6():. PubMed ID: 28813246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data.
    Sarangdhar M; Tabar S; Schmidt C; Kushwaha A; Shah K; Dahlquist JE; Jegga AG; Aronow BJ
    Nat Biotechnol; 2016 Jul; 34(7):697-700. PubMed ID: 27404875
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA's sentinel network: a monumental task.
    Young D
    Am J Health Syst Pharm; 2007 Apr; 64(8):800-1. PubMed ID: 17420189
    [No Abstract]   [Full Text] [Related]  

  • 11. Miscategorization of Deaths in the US Food and Drug Administration Adverse Events Database.
    Meier L; Wang EY; Tomes M; Redberg RF
    JAMA Intern Med; 2020 Jan; 180(1):147-148. PubMed ID: 31589249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor Use.
    Li AS; Pomeranz HD
    J Neuroophthalmol; 2016 Dec; 36(4):480-481. PubMed ID: 27851718
    [No Abstract]   [Full Text] [Related]  

  • 13. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
    de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
    PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scientists mine web search data to identify epidemics and adverse events.
    Kuehn BM
    JAMA; 2013 May; 309(18):1883-4. PubMed ID: 23652502
    [No Abstract]   [Full Text] [Related]  

  • 15. The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia.
    ; Andersen M; Bergman U; Choi NK; Gerhard T; Huang C; Jalbert J; Kimura M; Kimura T; Kubota K; Lai EC; Ooba N; Park BJ; Pratt N; Roughead EE; Sato T; Setoguchi S; Shin JY; Sundström A; Yang YH
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):700-4. PubMed ID: 23653370
    [No Abstract]   [Full Text] [Related]  

  • 16. Systematic identification of drugs that cause birth defects--a new opportunity.
    Mitchell AA
    N Engl J Med; 2003 Dec; 349(26):2556-9. PubMed ID: 14695418
    [No Abstract]   [Full Text] [Related]  

  • 17. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing surveillance and other epidemiologic uses of drug prescription data in the United States.
    Strom BL
    Ann Ist Super Sanita; 1991; 27(2):235-7. PubMed ID: 1755576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More eyeballs on AERS.
    Pratt LA; Danese PN
    Nat Biotechnol; 2009 Jul; 27(7):601-2. PubMed ID: 19587659
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.